Markus Warmuth
InvestorVenture Partner at Versant Ventures · M.D., Chief Executive Officer at Monte Rosa Therapeutics
Cambridge, Massachusetts
Writes $100K – $5M checks · typically $1.5M
Find your path to Markus
218 people in our graph share verified history with Markus — schools, employers, funds. One of them is your warm intro.
Walter KowtoniukunlockedMarkus: together at Third Rock Ventures (2018–2019)
Markus: together at Ventus Therapeutics
×10Markus: together at Third Rock Ventures
About
Markus Warmuth serves as Chief Executive Officer at Monte Rosa Therapeutics and is a board member at Ventus Therapeutics. He is a physician scientist with experience in drug discovery, translational research, and clinical development across the pharmaceuticals industry.
M.D., Chief Executive Officer at Monte Rosa Therapeutics
Intro paths
→
In turn, Markus can intro founders to Monte Rosa Therapeutics's investors below.
Monte Rosa Therapeutics's investors · 8
Aisling CapitalNew YorkAmzak HealthNew YorkAvoro Capital AdvisorsNew YorkDimension CapitalSan Francisco · $1M – $10M checksGV (Google Ventures)Mountain View · $250K – $50M checksHBM PartnersZug · $5M – $50M checksNew Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2020Versant VenturesSan Francisco · $250K – $5M checks
Experience
- Ventus TherapeuticsMember Board Of Directorscurrent2021 — present
- Monte Rosa TherapeuticsChief Executive Officercurrent2019 — presentBasel Area, Switzerland and Cambridge, MA
- Versant VenturesVenture Partnercurrent2019 — presentBoston, Massachusetts
- IMV Inc.Independent Board Member2018 — 2023
- Third Rock VenturesEntrepreneur In Residence2018 — 2019Boston, Massachusetts
- Relay TherapeuticsIndependent Board Member2017 — 2018Cambridge, Massachusetts
- H3 BiomedicinePresident and Chief Executive Officer2011 — 2018
- H3 BiomedicineChief Scientific Officer2011Cambridge, Massachusetts, USA
- Novartis Institutes for BioMedical Research (NIBR)Executive Director and Head of Oncology Drug Dicovery2008 — 2011
- Genomics Institute of the Novartis Research FoundationDirector Kinase Platform2002 — 2008
- Ludwig-Maximilians Universität MünchenMD1998 — 2002
Skills & more
Biotechnology46Drug Discovery79Oncology93Cancer38Lifesciences17Molecular Biology26Drug Development58Genomics49High Throughput Screening6Biochemistry20Immunology12Clinical Development18
+12 more
CellCell BiologyIn VitroCell CulturePharmacologyAntibodiesAssay DevelopmentBiomarkersPharmaceutical IndustryTranslational MedicineClinical TrialsCancer ResearchFrom Markus's professional profile.
Deals · 1
Ventus TherapeuticsBoard seat
via Versant Ventures · filed Feb 2022 · $140M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Versant Ventures
Alex Mayweg
Managing Director at Versant Ventures
Alicia Levey
Venture Partner at Versant Ventures
Andrew Jefferson
Operating Partner at Versant Ventures
Ariel Kantor
Principal at Versant Ventures
Barbara Lubash
Managing Director at Versant Ventures
Beckie Robertson
Venture Advisor at Intuitive Ventures
Brad Bolzon
Chairman, Managing Director at Versant Ventures
Brian Atwood
Managing Director at Versant Ventures
Frequently asked questions
- Who is Markus Warmuth?
- Markus Warmuth serves as Chief Executive Officer at Monte Rosa Therapeutics and is a board member at Ventus Therapeutics. He is a physician scientist with experience in drug discovery, translational research, and clinical development across the pharmaceuticals industry.
- Where does Markus Warmuth work?
- Markus Warmuth is Venture Partner at Versant Ventures and M.D., Chief Executive Officer at Monte Rosa Therapeutics.
- What check size does Markus Warmuth write?
- Markus Warmuth typically writes checks of $100K – $5M.
- What boards does Markus Warmuth sit on?
- Markus Warmuth holds tracked board seats at Ventus Therapeutics.
- Where did Markus Warmuth go to school?
- Markus Warmuth studied at Ludwig-Maximilians-Universität München (MD, Medicine).
Founder mafias
Ludwig-Maximilians-Universität München mafia83
Also came through, then founded or led a company.
Toby TriebelMaster of Business ResearchFounded Spotcap +1Anselm BauerDiplomaFounded Stylight +1Roman SchumacherBachelor of ScienceFounded Personio +1Benjamin GuentherDipl. Kfm.Founded Stylight +1Reinhard MeierMedical SchoolFounded TeleClinic +1Till WagnerMaster of Science - MSFounded askLio +1
+ 76 more
Third Rock Ventures mafia23
Also came through, then founded or led a company.
Reid HuberPartnerFounded MOMA Therapeutics +2Alexis BorisyPartnerFounded Foundation Medicine +2Christoph LengauerPartnerFounded Celsius Therapeutics +2Steve PaulVenture PartnerFounded Voyager Therapeutics, Inc. +1Philip ReillyVenture PartnerFounded Luna Genetics +1Uday KumarEntrepreneur-in-ResidenceFounded Element Science +1
+ 16 more
Versant Ventures mafia12
Also came through, then founded or led a company.
Peter EmtageVenture PartnerFounded Santa Ana +1Erik T. EngelsonVenture PartnerFounded Medina Medical +1Mike RosenbluthInvestment ProfessionalFounded Swing +1Rami HannoushVenture PartnerFounded Epi BiologicsBryan BergCBO-in-ResidenceFounded StandardcapBeckie RobertsonManaging DirectorFounded Egis
+ 5 more
Same school
Also attended Ludwig-Maximilians-Universität München220
Julia SchrameierAssociate at Manta Ray VenturesCeline XiaoInvestor at DN CapitalFriedrich von WulffenPrincipal at Burda Principal InvestmentsElçinTalent Team at Hummingbird VenturesLaura WeigertSenior Associate at Marlin Equity PartnersToby TriebelPartner at FinTech Collective
+ 214 more
Shared employers
Also worked at Monte Rosa Therapeutics3
Also worked at IMV Inc.3
Also worked at Third Rock Ventures87
Lisa PurcellInvestor at Third Rock VenturesPaul MeloneInvestor at Third Rock VenturesLee VeneziaInvestor at Third Rock VenturesKevin MunnellyInvestor at Third Rock VenturesAmanda ChanInvestor at Third Rock VenturesJigar RaythathaInvestor at Third Rock Ventures
+ 81 more
Also worked at Relay Therapeutics11
Anneli MathesonExecutive Assistant at Prelude VenturesJulia PianSenior Associate at Atlas VentureEli CasdinChief Investment Officer and Founder at Casdin CapitalDeborah PalestrantPartner, Executive Chair, 4:59 Initiative at 5AM VenturesKori RahaimSenior Vice President, Head of People and 4:59 Initiative Business Operations at 5AM VenturesJakob LovenPartner at Nextech Invest
+ 5 more